Selected article for: "disease onset and IgG antibody"

Author: Lucas, Carolina; Klein, Jon; Sundaram, Maria; Liu, Feimei; Wong, Patrick; Silva, Julio; Mao, Tianyang; Oh, Ji Eun; Tokuyama, Maria; Lu, Peiwen; Venkataraman, Arvind; Park, Annsea; Israelow, Benjamin; Wyllie, Anne L.; Vogels, Chantal B. F.; Muenker, M. Catherine; Casanovas-Massana, Arnau; Schulz, Wade L.; Zell, Joseph; Campbell, Melissa; Fournier, John B.; Grubaugh, Nathan D.; Farhadian, Shelli; Wisnewski, Adam V.; Cruz, Charles Dela; Omer, Saad; Ko, Albert I.; Ring, Aaron; Iwasaki, Akiko
Title: Kinetics of antibody responses dictate COVID-19 outcome
  • Cord-id: ezhwnj12
  • Document date: 2020_12_22
  • ID: ezhwnj12
    Snippet: Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization
    Document: Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization and clinical parameters associated with worse clinical progression. While high anti-S IgG levels correlated with worse disease severity, such correlation was time-dependent. Deceased patients did not have higher overall humoral response than live discharged patients. However, they mounted a robust, yet delayed response, measured by anti-S, anti-RBD IgG, and neutralizing antibody (NAb) levels, compared to survivors. Delayed seroconversion kinetics correlated with impaired viral control in deceased patients. Finally, while sera from 89% of patients displayed some neutralization capacity during their disease course, NAb generation prior to 14 days of disease onset emerged as a key factor for recovery. These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levels per se, but rather with the delayed kinetics of NAb production.

    Search related documents:
    Co phrase search for related documents
    • adaptive innate and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8
    • adaptive innate and longitudinal analysis: 1, 2, 3, 4, 5, 6, 7, 8